

Supplementary Table 2 Breast cancer patients who do not carry a *BRCA1/2* germline mutation, treated with neoadjuvant chemotherapy: clinico-pathological characteristics and response to treatment

| ID | Age at diagnosis | cT (cm) | cN | Histological type | Grade | ER status | Neoadjuvant chemotherapy | Tamoxifen* | Clinical response | Pathological response |
|-------|------------------|---------|----|-------------------|-------|-----------|--------------------------|------------|-------------------|-----------------------|
| 1279 | 36.7 | 2.5 | 1 | Ductal | 3 | Neg | ACx4 | Yes | Complete | Complete |
| 1191 | 39.3 | 8.0 | 1 | Ductal | 2‡ | NA | ACx4 | No | Complete | Incomplete |
| AJ59 | 47.5 | 10.0 | 0 | Ductal | 3 | Pos | ECx6 | No | Complete† | Incomplete |
| AJ79 | 60.8 | 1.0 | 0 | Ductal | 1‡ | Pos‡ | ACx4 | No | Complete | Incomplete |
| AJ115 | 50.4 | 3.5 | 0 | Adenoca | 3‡ | Neg‡ | ACx4 | No | Complete | Incomplete |
| AJ279 | 52.8 | 2.0 | 0 | Ductal | 2‡ | Neg‡ | ACx4 | No | Complete | Incomplete |
| FC117 | 54.6 | 3.2 | 0 | Ductal | 3 | Pos | ACx4 | Yes | Complete | Incomplete |
| 1250 | 40.0 | 2.0 | 0 | Ductal | NA | Pos | ACx4 | Yes | Complete | Incomplete |
| AJ396 | 58.2 | 10.0 | 0 | Ductal | 3 | Neg | FACx6 | No | Partial† | Incomplete |
| AJ32 | 46.2 | 11.0 | 0 | Ductal | 3‡ | Neg‡ | Px4 | No | Partial | Incomplete |
| AJ84 | 54.8 | 5.0 | 1 | Ductal | 3 | Neg‡ | ACx4 | No | Partial | Incomplete |
| AJ142 | 44.8 | 2.0 | 0 | Ductal | 3‡ | Pos‡ | ACx4 | No | Partial | Incomplete |
| FC59 | 58.0 | 5.0 | 0 | Ductal | 2‡ | Pos‡ | ACx4 | Yes | Partial | Incomplete |
| FC80 | 48.0 | 4.0 | 0 | Ductal | 1‡ | Pos‡ | ACx4 | Yes | Partial | Incomplete |
| J418 | 38.2 | 2.5 | 0 | Ductal | 2 | NA | ACx4 | No | Partial | Incomplete |
| 1129 | 34.8 | 6.0 | 1 | Ductal | 2 | Pos‡ | ACx4 | No | Partial | Incomplete |
| 1138 | 39.2 | 3.4 | 1 | Ductal | 1 | Pos‡ | ACx4 | Yes | Partial | Incomplete |
| 1139 | 35.3 | 3.0 | 0 | Ductal | 3 | Pos‡ | ACx4 | Yes | Partial | Incomplete |
| 1179 | 34.3 | 2.8 | 0 | Ductal | 2‡ | Pos‡ | ACx4 | Yes | Partial | Incomplete |
| 1209 | 35.9 | 6.0 | 0 | Ductal | 3 | Neg | ACx4 + Dx4 | Yes | Partial† | Incomplete |
| 1218 | 39.9 | 3.0 | 0 | Ductal | 3‡ | Pos | ACx4 | Yes | Partial | Incomplete |
| 1238 | 39.7 | 4.0 | 1 | Ductal | 3 | Pos | ACx4 | No | Partial | Incomplete |
| 1249 | 38.9 | 2.6 | 0 | Ductal | 1 | Pos | ACx4 | Yes | Partial | Incomplete |
| 98114 | 70.1 | 4.5 | 0 | Ductal | NA | Pos‡ | ACx4 | Yes | Partial | Incomplete |
| AJ156 | 48.7 | 7.0 | 0 | Ductal | 3‡ | Pos‡ | ACx5 | No | Partial† | Incomplete |
| AJ386 | 57.7 | 12.0 | 1 | Ductal | 3‡ | Neg | FACx6 | No | No change† | Incomplete |
| 97008 | 79.4 | 5.0 | 0 | Ductal | 3‡ | Neg‡ | ACx4 | No | No change | Incomplete |

A, doxorubicin (Adriamycin®); adenoca, adenocarcinoma; C, cyclophosphamide; cN, clinical axillary lymph node status; cT, clinical tumour size; D, docetaxel (Taxotere®); E, epirubicin; ER, oestrogen receptor; F, 5-fluorouracil; NA, not available; Neg, negative; P, paclitaxel (Taxol®); Pos, positive.

*Concomitant administration with the neoadjuvant chemotherapy.

†Evaluated after four cycles of chemotherapy.

‡Evaluated after the neoadjuvant chemotherapy (at the time of surgery).